ASCO 2018 June 1 - 5th, 2018 | Chicago, IL

ASCO is supported by its affiliate organization, the Conquer Cancer Foundation, which funds ground-breaking research and programs that make a tangible difference in the lives of people with cancer. This annual meeting is one of the largest oncology conferences there is and will bring together more than 32,000 oncology professionals from around the world to discuss state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field.

We hope to see you there and set up a meeting with one of our oncology scientific leaders to discuss how we can further streamline your clinical trial!

AACR-ASCO

George Clinical's Scientific Leadership in Attendance

Glenn Kerkhof, BCom, MBA

  • Board Member, George Clinical
  • Executive Chairman, George Clinical

Glenn Kerkhof is Executive Chairman of George Clinical. Glenn has over 27 years’ experience in the contract research or drug development industry and joined George Clinical from Chiltern, where he was Chief Executive Officer. Before Chiltern, Glenn served as Vice President, Clinical Services for Charles River Laboratories, and as Vice President, Clinical Europe for Inveresk Research. Also, he is a non-executive director of Immunoglobal Pty. Ltd and his previous directorships include Cell Care Pty. Ltd. Glenn, based in Melbourne, works closely with the executive team to formulate and execute George Clinical’s global strategy.

Sean Hart

  • Chief Business Officer

As Chief Business Office for George Clinical, Sean Hart leads the U.S. and Asia-Pacific business development teams and directs global marketing and public relations efforts for George Clinical. Prior to joining George Clinical, Sean was the Executive Vice President and Managing Director of Vector Oncology overseeing the Global Pharma Services team including early phase and observational research. Sean is a recognized industry leader in Phase IV clinical trials, post-marketing surveillance programs, and patient registries. His experience spans all major therapeutic areas and all phases of research and development.

Dr. Ari VanderWalde is an internationally recognized researcher providing expertise in oncology clinical trials with a focus on immune therapies in solid tumors and melanoma. He has worked in the pharmaceutical industry helping lead the approval of a new compound in Melanoma. Along with this experience, he also works at a premier cancer research institute and as a scientific expert in a global CRO specializing in oncology. 

In addition, Dr. VanderWalde has collaborated and participated on advisory boards with many of the nation’s thought leaders and top experts in the field and holds a dual appointment with the University of Tennessee Health Science Center as Associate Vice Chancellor of Research and Assistant Professor, Hematology/Oncology. He is involved in research that can improve treatment for cancer patients by targeting therapy in a more personalized fashion based on immune markers and aberrations in cancer genetics.

Event Location

McCormick Place
2301 S King Dr
Chicago, IL
USA

Attending this event?

Meet with George Clinical! Contact us to schedule a time now.

required
required
required
required
I wish to subscribe to George Clinical communications.
required

Add George Clinical to your network